Hisamitsu Pharmaceutical CoFSE:4530 89 Return-on-Tangible-Asset is 5.84% as of Nov. 2025, which is 0% below its 10-year median of 5.86. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 1,009 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 61.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hisamitsu Pharmaceutical Co's annualizedNet Income for the quarter that ended in Nov. 2025 was 円19,472 Mil. Hisamitsu Pharmaceutical Co's average total tangible assets for the quarter that ended in Nov. 2025 was 円333,595 Mil. Therefore, Hisamitsu Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Nov. 2025 was 5.84%.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
FSE:4530'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.06 Med: 5.86 Max: 7.48
Current: 5.65
During the past 13 years, Hisamitsu Pharmaceutical Co's highest Return-on-Tangible-Asset was 7.48%. The lowest was 3.06%. And the median was 5.86%.
FSE:4530's Return-on-Tangible-Asset is ranked better than 61.84% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs FSE:4530: 5.65
Hisamitsu Pharmaceutical Co (FSE:4530) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset Chart
FSE:4530 vs ESPR, AMPH, ETON: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Nov. 2025) net income data.
What does a Return-on-Tangible-Asset of 5.84% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Return-on-Tangible-Asset of 5.84% as of Nov. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 5.86. Over the past decade, Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 3.06 to 7.48. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #385 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 38.2%.
Is Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset too high?
Hisamitsu Pharmaceutical Co's current Return-on-Tangible-Asset of 5.84% is near median its 10-year median of 5.86. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 7.48. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Hisamitsu Pharmaceutical Co's value of 5.84% is 84.8% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #385 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Return-on-Tangible-Asset compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #385 out of 1009 companies for Return-on-Tangible-Asset. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Hisamitsu Pharmaceutical Co's value of 5.84% is 84.8% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 3.06 to 7.48 over the past decade. While the company's 10-year median is 5.86 vs. the industry median of 3.16, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Return-on-Tangible-Asset of 5.84% is 84.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Return-on-Tangible-Asset is 5.84%, which is near median its own 10-year median of 5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Return-on-Tangible-Asset of 5.84%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Return-on-Tangible-Asset is 5.84%, which is near median its 10-year median of 5.86 and 84.8% above the Drug Manufacturers industry median of 3.16. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Return-on-Tangible-Asset is 5.84% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Return-on-Tangible-Asset: 5.84% (near median its 10-year median of 5.86)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 84.8% above the Drug Manufacturers median (#385 of 1009)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
